Streetbeat News

Revenues

TKC

Turkcell Iletisim Hizmetleri has revised its revenue growth and EBITDA guidance for 2023 upward to around 73% and approximately TRY 39 billion, respectively. The company maintains its operational capital expenditures to sales ratio guidance at approximately 22%.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:32 am

BDSX

Biodesix has adjusted its 2023 financial outlook due to a change in the timing and assumptions regarding the anticipated collection of revenue from a backlog of previously unrecognized Medicare Advantage claims. The company now expects to generate $50 to $52 million in total revenue in 2023, down from the previous estimate of $53.29 million.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:31 am

LAB

Standard BioTools has projected its total revenue for FY23 to be between $100M and $105M. The company also anticipates a non-GAAP gross margin of approximately 60%.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:29 am

PWSC

PowerSchool, listed as PWSC, has projected its total revenue for 2023 to be between $697.5M and $700.5M. The company also expects its Q4 revenue to range from $182M to $185M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:20 pm

CTOS

Custom Truck One Source (CTOS) has affirmed its full-year 2023 EBITDA guidance and raised its revenue outlook from $1.725B-$1.83B to $1.765B-$1.87B.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:14 pm

NDLS

Noodles has revised its 2023 total revenue outlook from $500M-$510M to $502M-$506M. The company also adjusted its EPS from ($0.11)-$0.00 to ($0.08)-$0.00.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:09 pm

EC

Ecopetrol has reported a 19.1% decline in total sales for Q3, with an EBITDA margin of 45.7%.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 11:06 pm

AGTI

Agiliti has reaffirmed its 2023 revenue outlook of $1.16 billion to $1.19 billion, with an adjusted EPS of $0.54 to $0.59.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:56 pm

PLUS

ePlus has maintained its FY24 revenue guidance of $2.23B-$2.33B, and an adjusted EBITDA range of $200M-$215M, representing a margin of 9.0%-9.2%.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:50 pm

COLL

Collegium Pharmaceutical has revised its 2023 product revenues and net outlook from $565M-$580M to $565M-$570M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 10:46 pm